Affiliation:
1. Department of Biomedical Laboratory Science and Management, Vidyasagar University, West Bengal, India
2. Department
of Microbiology, Nil Ratan Sirkar Medical College and Hospital, Kolkata, West Bengal, India
Abstract
Background:
Emerging antibiotic resistance (ABR) in Proteus spp., especially to third-generation cephalosporins (3GCc), carbapenems, and fluoroquinolones, challenges the treatment outcome and infection prevention. Limited studies pose a knowledge gap between them and ABR.
Methods:
We investigated the in vitro efficacy of therapeutic options and prevalence of β-lac-tamase and plasmid-mediated quinolone resistance (PMQR) traits in 3GC- and/or fluoroquino-lone-nonsusceptible Proteus (P.) spp. (n=27) in Kolkata, India, during 2021–2022. P. mirabilis was commonly isolated (>80%) from superficial and urine samples. The majority of the isolates (48-78%) remained susceptible to piperacillin-tazobactam, meropenem, amikacin, cefoperazone-sulbactam, and cefepime.
Results:
All isolates showed >0.2 multiple-antibiotic resistance index, with >65% being multi-drug and >30% being extensively drug-resistant. blaTEM (n=9), blaNDM (n=9), and qnrA (n=6) were commonly noted with the co-production of β-lactamases and PMQR in ten (37%) isolates. More than 50% of the isolates were devoid of the tested acquired genes.
Conclusion:
The study concludes that superbugs dominate, with limited occurrence of plasmid-borne markers in this geographic location.
Funder
Indian Council of Medical Research (ICMR), New Delhi, India
Publisher
Bentham Science Publishers Ltd.